An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leuprorelin (Primary)
Indications Precocious puberty
Focus Adverse reactions
Sponsors Takeda

Most Recent Events

23 Dec 2021 Results assessing efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children published in the Medicine
19 Dec 2018 Status changed from active, no longer recruiting to completed.
11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 31 Dec 2018.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight